Related Experiment Video

Updated: May 13, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Impact of genetic alterations on mTOR-targeted cancer therapy

Shi-Yong Sun1

  • 1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA. ssun@emory.edu

Chinese Journal of Cancer
|March 16, 2013
PubMed

Insights

Rapamycin drugs show modest effects alone in cancer. Genetic mutations impacting the mechanistic target of rapamycin (mTOR) pathway may improve cancer treatment strategies involving rapalogs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Rapamycin and its derivatives (rapalogs) are allosteric inhibitors of the mechanistic target of rapamycin (mTOR) pathway.
  • While approved for some cancers, their efficacy as single agents is often limited.
  • The mTOR pathway is crucial in cancer and is regulated by upstream signaling pathways with frequent genetic alterations.

Purpose of the Study:

  • To review research on the impact of genetic alterations on rapalog-based cancer therapy.
  • To explore the potential of targeting the mTOR axis in cancer treatment.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of genetic mutations in key mTOR pathway components (e.g., PIK3CA, KRAS, PTEN, LKB1).
  • Examination of how these mutations influence mTOR hyperactivation and cancer cell dependency.

Main Results:

  • Genetic alterations in upstream signaling pathways can lead to addiction to mTOR hyperactivation in certain cancers.
  • Understanding these mutations is key to predicting and improving responses to mTOR-targeted therapies.
  • Research is advancing to demonstrate the therapeutic potential of stratifying patients based on genetic profiles.

Conclusions:

  • Genetic landscape of cancer significantly influences the efficacy of mTOR-targeted therapies.
  • Personalized approaches considering specific mutations may enhance the clinical utility of rapalogs.
  • Further research is needed to fully leverage genetic insights for optimizing cancer treatment.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...